Gujarat inject Kerala Limited has announced its unaudited standalone financial results for the third quarter and nine months ended December 31, 2025. The Board of Directors approved these results during their meeting held on February 14, 2026, with the statutory auditors M/s. S. Mandawat & Co. conducting a limited review of the financial statements.

Financial Performance Overview

The company's financial performance for the quarter and nine-month period shows significant revenue growth compared to the previous year. The results demonstrate the company's operational progress across different reporting periods.

Quarterly Results Analysis

For the third quarter ended December 31, 2025, Gujarat Inject Kerala Limited reported revenue from operations of ₹162.51 lakh, marking a substantial increase from ₹13.80 lakh in the corresponding quarter of the previous year. However, the net profit for the quarter decreased to ₹3.80 lakh compared to ₹6.75 lakh in Q3FY25.

The company's total expenses for Q3FY26 stood at ₹171.32 lakh, while the profit before tax was ₹5.08 lakh. Current tax expense for the quarter amounted to ₹1.28 lakh.

Nine-Month Performance

For the nine months ended December 31, 2025, the company achieved revenue from operations of ₹502.26 lakh, significantly higher than ₹19.64 lakh in the corresponding period of the previous year. Net profit for the nine-month period was ₹94.40 lakh compared to ₹101.72 lakh in the previous year.

Share Capital and Earnings Per Share

The company's paid-up equity share capital remained constant at ₹1,463.48 lakh with a face value of ₹10.00 per share. Basic earnings per share from continuing operations for Q3FY26 was ₹0.03, compared to ₹0.05 in the corresponding quarter of the previous year.

Regulatory Compliance

The financial results were prepared in accordance with Indian Accounting Standards 34 "Interim Financial Reporting" as prescribed under Section 133 of the Companies Act, 2013. The company operates in a single reportable segment as per Indian Accounting Standard 108 on "Operating Segment". The Board meeting commenced at 3:00 PM and concluded at 3:35 PM on February 14, 2026, with all necessary approvals obtained for the quarterly results.

Gujarat inject (Kerala) Limited has announced a significant change in its board composition with the resignation of an Independent Director. The company communicated this development to the BSE on December 13, 2025, in compliance with regulatory requirements.

Director Resignation Details

Mrs. Reena Mahatma (DIN: 02846012) has resigned from her position as Non-Executive Independent Director of the company. The resignation became effective from the close of business hours on December 9, 2025. The formal resignation process was initiated through a resignation letter dated December 8, 2025, which the company received on December 9, 2025.

Reason for Departure

In her resignation letter, Mrs. Mahatma cited pre-occupation elsewhere and other personal commitments as the primary reasons for stepping down from her directorship. She confirmed that there were no other reasons beyond those stated for her resignation. The director also acknowledged that the company had cleared all her dues and confirmed she had no outstanding claims from the organization.

Regulatory Compliance

The company has fulfilled its disclosure obligations under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The notification was made in accordance with SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, which governs the disclosure requirements for changes in board composition.

Company Communication

The formal communication to BSE was signed by Murlish Ivshankar Annair, Whole-Time Director (DIN: 02243039), on behalf of Gujarat Inject (Kerala) Limited. The company's registered office is located in Vadodara, Gujarat, and it operates under CIN: L46309GJ1991PLC151872 with BSE scrip code 524238.